PGPE Ltd publishes April NAV

(LSE: PEY/PEYS)

Partners Group Private Equity Limited

NAV decreased by 2.5% in April

· NAV decreased to EUR 12.26 per share, corresponding to EUR 830.13 million

· Portfolio revaluations (-1.8%) and negative currency movements (-0.7%)

· PGPE Ltd received distributions of EUR 23.9 million during the month

In April, PGPE Ltd's NAV declined by 2.5%, primarily due to the revaluation of specific assets in the private equity portfolio including Pharmathen, a developer of advanced drug delivery technologies, and United States Infrastructure Corporation ("USIC"), a US based provider of underground utility locating services. This decline was partially offset by the positive performance of listed assets.

Despite major operational turnaround initiatives over the last year, Pharmathen became subject to an FDA Import Alert which restricts supply to the US market. Based on the updated outlook, the implied enterprise value is unlikely to be sufficient to cover the company's existing debt, and the investment was therefore written down to zero. In light of recent exceptional customer insourcing initiatives and operational headwinds, the valuation of USIC was also prudently adjusted down in April to reflect lower anticipated earnings growth. Partners Group continues to work closely with the company's board and management team on operational and commercial initiatives to support value creation.

Distribution activity remained robust during the month, with PGPE Ltd receiving a total of EUR 23.9 million, driven primarily by proceeds from the sale of Clario, a US-based health tech company that helps drug developers run clinical trials more effectively by using digital tools to collect and analyze patient data, including through wearable devices, imaging, and remote monitoring solutions. The business was sold to Thermo Fisher Scientific at an enterprise value of USD 9.4 billion. Since 2020, the company has scaled materially through strong organic growth, the roll out of a more integrated and SaaS oriented technology platform, AI enabled product development, and its strategic merger with Bioclinica, collectively expanding its global footprint, customer base, and operating scale.

On the capital allocation side, PGPE Ltd announced a further EUR 18 million allocation to its share buyback program under the capital allocation policy adopted in March 2024. Together with the residual value from the October 2025 allocation, the program amounted to EUR 18.1 million as at 30 April 2026. The program will expire on 31 July 2026.

Post month-end, the Board of PGPE Ltd declared a first interim dividend of EUR 0.325 per share for FY 2026 (amounting to EUR 22.1 million), consistent with previous guidance to distribute 5% per annum of the prior year's closing NAV through semi-annual payments. The first interim dividend will be paid to shareholders on 19 June 2026.

Further details on these developments, alongside key portfolio updates for the first quarter of 2026, are available in the recent quarterly update webcast that can be viewed here.

Ends.

About Partners Group Private Equity Limited

PGPE Ltd is an investment holding company founded in 1999 and domiciled in Guernsey. It invests in private equity direct investments. PGPE Ltd is managed in its investment activities by Partners Group, one of the largest firms in the global private markets industry, with USD 185 billion in investment programs under management in private markets, of which USD 86 billion is in private equity. Partners Group itself is listed on the Swiss Stock Exchange (ticker: PGHN). PGPE Ltd aims to provide shareholders with long-term capital growth and an attractive dividend yield. PGPE Ltd is traded on the Main Market of the London Stock Exchange (ticker: PEY for the Euro quote; PEYS for the Sterling quote).

Contacts

Partners Group Private Equity Limited:

[email protected]

www.partnersgroupprivateequitylimited.com

Registered Number: 35241 LEI: 54930038LU8RDPFFVJ57

Notes:

1. Note that references in this announcement to Partners Group Private Equity Limited have been abbreviated to "PGPE Ltd" or "the Company". References to Partners Group AG have been abbreviated to "Partners Group" or "the Investment Manager".

2. This document does not constitute an offer to sell or a solicitation of an offer to buy or subscribe for any securities and neither is it intended to be an investment advertisement or sales instrument of Partners Group Private Equity Limited. The distribution of this document may be restricted by law in certain jurisdictions. Persons into whose possession this document comes must inform themselves about and observe any such restrictions on the distribution of this document. In particular, this document and the information contained therein are not for distribution or publication, neither directly nor indirectly, in or into the United States of America, Canada, Australia or Japan.

3. This document may have been prepared using financial information contained in the books and records of the product described herein as of the reporting date. This information is believed to be accurate but has not been audited by any third party. This document may describe past performance, which may not be indicative of future results. No liability is accepted for any actions taken on the basis of the information provided in this document. Neither the contents of PGPE Ltd's website nor the contents of any website accessible from hyperlinks on PGPE Ltd's website (or any other website) are incorporated into, or form part of, this announcement.